European CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
You may also be interested in...
Sales grew but operating profits remained flat in 2019 at Orion Group, as the European mid-sized pharma pursued R&D in amyotrophic lateral sclerosis and cancer.
Recommendations from the European Medicines Agency explain the conditions under which early access to remdesivir could be given through compassionate use programs.
The regulatory agency also urges qualified persons at drug companies to let the agency know as soon as possible if they are finding that the new measures are not flexible enough to deal with the current logistical challenges quickly.